Skip to main content
SpringerLink
Log in

Other New Agents for Hodgkin Lymphoma

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1561 Accesses

Abstract

The efficacy seen with brentuximab vedotin (BV) has set the bar high for evaluating other new agents in Hodgkin lymphoma (HL). Several additional promising agents are being investigated for HL, and while no single agent has yet demonstrated response rates as high as BV, these agents are good candidates for building combinations. A lot has been learned about the underlying biology of HL that has revealed potential targets for therapy. HL tumors are characterized by their extensive microenvironments made up primarily of T cells as well as eosinophils, B lymphocytes, and plasma cells that surround the rare tumor cells called Reed-Sternberg (RS) cells. There is extensive cross talk through cytokines and chemokines between RS cells and the surrounding inflammatory infiltrate which contributes to support of RS cell survival and suppression of antitumor immunity. Newer agents for HL (summarized in Table 22.1) target the various aspects of HL biology and include PI3K/Akt/mTOR pathway inhibitors, histone deacetylase (HDAC) inhibitors, and immune modulators.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Steidl C, Connors JM, Gascoyne RD (2011) Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 29:1812–1826

    Article  CAS  PubMed  Google Scholar 

  2. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG (2005) Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 205:498–506

    Article  CAS  PubMed  Google Scholar 

  3. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A (2006) Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 132:503–511

    CAS  PubMed  Google Scholar 

  4. Johnston PB P-BL, Rogerio J, Warsi G, White K, Ramchandren R (2013) Phase 2 study everolimus for relapsed/refractory classical Hodgkin lymphoma. Haematologica 98:Abstract 126

    Google Scholar 

  5. Meadows SA, Kashishian A, Johnson D, Diehl V, Lannutti B (2010) CAL-101, a potent selective inhibitor of the p110{delta} isoform of phosphatidylinositol 3-kinase, attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 116:3926

    Google Scholar 

  6. Younes A, Moskowitz AJ, Moskowitz CH, Fanale MA, Shustov A, Peterman S, Johnson D, Zhou L, Dansey DR, Godfrey WR, Gopal AJ (2013) Pilot phase 2 study of idelalisib, a selective inhibitor of PI3K-delta, in patients with heavily pretreated Hodgkin lymphoma. Hematol Oncol 31:Abstract 139

    Google Scholar 

  7. Lemoine M, Derenzini E, Buglio D et al (2012) The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012. 119(17): p. 4017-25.

    Google Scholar 

  8. Oki Y, Buglio D, Fanale M et al (2013) Phase I study of Panobinostat plus Everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 19:6882–6890

    Article  CAS  PubMed  Google Scholar 

  9. Lewis T, McCormick R, Zeng W et al (2011) Auristatin-based antibody-drug conjugates are synergistic in combination with PI3K-AKT-mTOR pathway inhibitors in hematologic malignancies and carcinoma. American Association for Cancer Research Annual Meeting 2011:Abstract 1789

    Google Scholar 

  10. Buglio D, Georgakis GV, Hanabuchi S et al (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112:1424–1433

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A (2011) HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 117:2910–2917

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Kirschbaum MH, Goldman BH, Zain JM et al (2007) Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517. Blood (ASH Annual Meeting Abstracts) 110:2574

    Google Scholar 

  13. Younes A, Sureda A, Ben-Yehuda D et al (2012) Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 30:2197–2203

    Article  CAS  PubMed  Google Scholar 

  14. Younes A, Oki Y, Bociek RG et al (2011) Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 12:1222–1228

    Article  CAS  PubMed  Google Scholar 

  15. Younes A, Hernandez F, Bociek RG et al (2011) The HDAC inhibitor entinostat (SNDX-275) induces clinical responses in patients with relapsed and refractory Hodgkin’s Lymphoma: results of ENGAGE-501 multicenter phase 2 study. Blood (ASH Annual Meeting Abstracts) 118:2715

    Google Scholar 

  16. Martín-Sánchez E, Sánchez-Beato M, Rodríguez ME et al (2011) HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. Br J Haematol 152:352–356

    Article  PubMed  Google Scholar 

  17. Fanale MA, Westin JR, Fowler N et al (2013) A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL). Blood 122:252

    Article  Google Scholar 

  18. Kotla V, Goel S, Nischal S et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36

    Article  PubMed Central  PubMed  Google Scholar 

  19. Boll B, Borchmann P, Topp MS et al (2010) Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 148:480–482

    Article  PubMed  Google Scholar 

  20. Fehniger TA, Larson S, Trinkaus K et al (2011) A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 118:5119–5125

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Moskowitz AJ, Hamlin PA Jr, Perales MA et al (2013) Phase II study of bendamustine in relapsed and refractory Hodgkin Lymphoma. J Clin Oncol 31:456–460

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

    Article  CAS  PubMed  Google Scholar 

  23. Keir M, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704

    Article  CAS  PubMed  Google Scholar 

  24. Yamamoto R, Nishikori M, Kitawaki T et al (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111:3220–3224

    Article  CAS  PubMed  Google Scholar 

  25. Forero-Torres A, Leonard JP, Younes A et al (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146:171–179

    Article  CAS  PubMed  Google Scholar 

  26. Ansell SM, Horwitz SM, Engert A et al (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764–2769

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Alison J. Moskowitz

  2. Lymphoma Service, Memorial Sloan-Kettering Cancer Center, Memorial Hospital, 1275 York Avenue, New York, NY, 10065, USA

    Anas Younes MD

Authors
  1. Alison J. Moskowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anas Younes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alison J. Moskowitz .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Andreas Engert

  2. Memorial Sloan - Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Moskowitz, A.J., Younes, A. (2015). Other New Agents for Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12505-3_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12504-6

  • Online ISBN: 978-3-319-12505-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation